Phase II Trial of Bevacizumab in Combination with XELOX in Colorectal Cancer Patients with Liver Metastases (H2, H3)

ABSTRACT: Interventions: Treatment is administered every 3 weeks until evidence of progression, unacceptable toxicity, patient refusal, or for a maximum of 9 cycles. During the treatment, image assessment is repeated every 3 cycles, and if liver metastases could be converted resectable, liver resection is performed. Primary outcome(s): resection rate of liver metastases Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Liver Metastases

PROVIDER: 2618368 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR